Participants may not have a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib; anticipation of need for major surgical procedures during the course of the study also excludes patients from the trial
Patients who have had or are planning to have the following invasive procedures are not eligible:\r\n* Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrollment\r\n* Subcutaneous port placement or central line placement is not considered major surgery; external central lines must be placed at least 3 days prior to enrollment and subcutaneous ports must be placed at least 7 days prior to enrollment\r\n* Core biopsy within 7 days prior to enrollment\r\n* Fine needle aspirate within 7 days prior to enrollment\r\n* NOTE: For purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapy
Major surgical procedure (including open biopsy, significant traumatic injury, etc.) within 28 days, or anticipation of the need for major surgical procedure during the course of the study as well as minor surgical procedure (excluding placement of a vascular access device or bone marrow biopsy) within 7 days prior to study enrollment
An open biopsy, non-healing wound, ulcer or significant traumatic injury within 28 days prior to starting treatment (percutaneous, endobronchial, and endoscopic biopsies are allowed)
Major surgical procedure or significant traumatic injury within 4 weeks prior to randomization and must have fully recovered from any such procedure or injury; planned surgery (if applicable) or the anticipated need for a major surgical procedure within the next six months. Note: the following are not considered to be major procedures and are permitted up to 7 days before randomization: Thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, and imaging-guided biopsy for diagnostic purposes
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study
Patients who have had significant traumatic injury within 28 days prior to enrollment are not eligible
No major surgical procedure or significant traumatic injury within 6 weeks prior to study registration, and must have fully recovered from any such procedure.
Significant traumatic injury within 3 weeks prior to planned initiation of study therapy
Major surgery, open biopsy or significant traumatic injury within 4 weeks prior to study entry
Major surgical procedure or significant traumatic injury within 28 days prior to study enrollment
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of treatment or anticipation of need for major surgical procedure during the course of the study
Traumatic injury within 2 weeks before initiation of study treatment
Patients who have had or are planning to have the following invasive procedures will be excluded:\r\n* Major surgical procedures, laparoscopic procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 therapy; subcutaneous port placement or central line placement is not considered major surgery, but must be placed greater than 48 hours from planned day 1 of therapy\r\n* Core biopsy within 7 days prior to day 1 therapy\r\n* Fine needle aspirate or central line placement within 48 hours prior to day 1 therapy\r\nNote: Routine bone marrow aspirate and biopsy for the purposes of disease staging are not part of these exclusion guidelines
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, or anticipation of need for major surgical procedure during the course of the study
Patients who have undergone major surgery (ie, intra-thoracic, intra abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of previous procedure or injury
Major surgery or significant traumatic injury within 14 days prior to therapy
Major surgical procedure or significant traumatic injury within 28 days before start of study registration
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Prior therapy:\r\n* Prior treatment with systemic immunosuppressive treatments, aside from systemic dexamethasone therapy for cerebral edema, such as methotrexate, chloroquine, azathioprine, etc. within 3 months of start of study therapy\r\n* Prior treatment with interstitial brachytherapy within 6 months of start of study therapy\r\n* Previous treatment with programmed death-protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) directed therapy\r\n* Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study\r\n* Minor surgical procedure (eg, stereotactic biopsy within 7 days of first study treatment; placement of a vascular access device within 2 days of first study treatment)
Major surgery or significant traumatic injury <28 days prior to the first RO6874281 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
Major surgical procedure or significant traumatic injury within 14 days of initiating study drug or anticipation of the need for major surgery during the study
Patients may have undergone a major or minor surgical procedure as long as the following apply:\r\n* Major surgical procedure, open biopsy or significant traumatic injury greater than 28 days prior to the first date of study therapy\r\n* Core biopsy or intravenous (IV) port placement greater than 7 days prior to the first date of study therapy
Patients who have had a major surgery or significant traumatic injury within 2 weeks of start of study drug
Major surgical procedure or significant traumatic injury within 28 days prior to study entry or anticipation of the need for major surgery during the course of study treatment
Major surgical procedure or significant traumatic injury within 14 days of initiating study drug or anticipation of the need for major surgery during the study
Major surgery or significant traumatic injury <28 days prior to Cycle 1 Day 1 (excluding fine needle biopsies) or anticipation of the need for major surgery during study treatment
Patients who have had or are planning to have the following invasive procedures will be excluded- Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1 therapy (Subcutaneous port placement or central line placement is not considered major surgery but must be placed greater than 48 hours from planned Day 1 of therapy); Core biopsy within 7 days prior to Day 1 therapy; Fine needle aspirate or central line placement within 48 hours prior to Day 1therapy.
Patients who have had or are planning to have the following invasive procedures are not eligible:\r\n* Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrollment\r\n* Central line placement or subcutaneous port placement is not considered major surgery; external central lines must be placed at least 3 days prior to enrollment and subcutaneous ports must be placed at least 7 days prior to enrollment\r\n* Core biopsy within 7 days prior to enrollment\r\n* Fine needle aspirate within 7 days prior to enrollment\r\n* Surgical or other wounds must be adequately healed prior to enrollment; Note: for purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapy
Major surgical procedure (including open biopsy, significant traumatic injury, etc.) within 28 days, or anticipation of the need for major surgical procedure during the course of the study as well as minor surgical procedure (excluding placement of a vascular access device or bone marrow biopsy) within 7 days prior to randomization.
Major surgical procedure or significant traumatic injury within 28 days prior to Day 1, Cycle 1, or anticipation of the need for major surgery during study treatment
Traumatic injury or palliative radiotherapy within 2 weeks prior study treatment initiation
Major surgery or significant traumatic injury within 60 days prior to enrollment
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgery or significant traumatic injury less than (<) 28 days prior to the first cergutuzumab amunaleukin infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Cycle 1, Day 1 or anticipation of need for major surgical procedure during the course of the study
Patients who have had major surgical procedures or significant traumatic injury within 28 days prior to study treatment
Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury
Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures (i.e. TURBT), percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury
Major surgery, open biopsy, significant traumatic injury within 28 days of starting treatment or anticipation of need for major surgical procedure during the course of the study
Invasive procedures defined as follows:\r\n* Major surgical procedure or significant traumatic injury within 28 days prior to day 1 therapy, or open biopsy within 7 days prior to day 1 therapy\r\n* Anticipation of need for major surgical procedures during the course of the study
=< 28 days before first dose of protocol-indicated treatment:\r\n* Anti-cancer treatment with bevacizumab.\r\n* Major surgery requiring general anesthesia or significant traumatic injury.
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 or anticipation of need for major surgical procedure during the course of the study
Patients who have had a major surgical procedure within 14 days of randomization. Patient has significant traumatic injury within 28 days before randomization.
Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study.
Major surgery or significant traumatic injury greater than or equal to 28 days prior to the first LMB-100 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
Had major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to day 1 of treatment on study
Patients must have fully recovered from the effects of any major surgery or significant traumatic injury within 14 days of course 1 day 1 (C1D1)
Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before first treatment
A major surgical procedure, open biopsy, or significant traumatic injury within 3 months prior to cycle 1 day 1 (percutaneous/endobronchial/endoscopic biopsies are allowed)
Stem cell infusion without traumatic brain injury
History of a major surgical procedure or a significant traumatic injury within 14 days prior to commencing treatment, or the anticipation of the need for a major surgical procedure during the course of the study.
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the start of study drug (56 days for hepatectomy, open thoracotomy, major neurosurgery) or anticipation of need for major surgical procedure during the course of the study (except for the planned metastasectomy)
Participants must have recovered from the effects of major surgery requiring general anesthesia or significant traumatic injury at least 14 days before treatment arm assignment
Major surgical procedure (including craniotomy and open brain biopsy) or significant traumatic injury within 14 days prior to registration or those patients who receive a non-central nervous system (CNS) minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 3 days prior to registration; there is no waiting period for central line placement; there is a 7-day window for recovery prior to registration for patients who underwent stereotactic biopsy of the brain
Patients with a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of therapy, or anticipation of need for major surgical procedure during the course of the study other than that defined by protocol are ineligible
Major surgery or significant traumatic injury within 14 days prior to Cycle 1 Day 1
Major surgical procedure or significant traumatic injury within 28 days prior to day 1 or anticipation of the need for major surgery during the course of study treatment
Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to “on-study” status
Subjects who have not recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment.
Major surgical procedure or significant traumatic injury within 28 days prior to study drug administration.
Patients who have had a major surgical procedure, open biopsy, or significant traumatic injury with poorly healed wound within 6 weeks prior to first dose of study drug; or anticipation of need for major surgical procedure during the course of the study (other than defined by protocol); or fine needle aspirations or core biopsies) within 7 days prior to first dose of study drug. NOTE: Patients will be allowed to start cycle 1 day 1 therapy after 24 hours from pre-treatment biopsy
Major surgical procedure with 4 weeks of first dose of study drug; open biopsy, or significant traumatic injury within 7 days prior to enrollment date; anticipation of need for major surgical procedure during the course of the study.
Recovery from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment
Major surgical procedure within 28 days prior to study treatment or anticipation of need for a major\r\nsurgical procedure during the course of the study
Major surgical procedure or significant traumatic injury within 4 weeks prior to study treatment, and must have fully recovered from any such procedure; and no date of surgery (if applicable) or anticipated need for a major surgical procedure planned within the next 6 months (Note: The following are not considered to be major procedures and are permitted up to 7 days prior to study treatment: Thoracentesis, paracentesis, port placement, laparoscopy, thorascopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures.)
(Bevacizumab-related exclusion) Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to study enrollment, or anticipation of need for major surgical procedure during the course of the study. For patients with brain tumors, craniotomy or intracranial biopsy sites must be adequately healed; free of drainage or cellulitis, and the underlying cranioplasty must appear intact at the time of study enrollment
FOR ALL PHASES (Ib AND II): Major surgical procedure or significant traumatic injury (as judged by the investigator) within 28 days before start of study medication, open biopsy within 7 days before start of study medication
Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before registration
Major surgical procedure or significant traumatic injury within 28 days before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days of day 1 of therapy.
Major surgical procedure or significant traumatic injury within 28 days before start of study medication
Major surgery or significant traumatic injury occurring within 21 days prior to treatment
Major surgery, open biopsy or significant traumatic injury within 28 days before the start of study treatment
A major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib (percutaneous/endobronchial biopsies are allowed)
Patients who have undergone major surgery (e.g. intra-thoracic, intra- abdominal or intra-pelvic), open biopsy or significant traumatic injury ? 4 weeks prior to starting study drug, or patients who have had minor procedures (i.e. transurethral resection of bladder tumor [TURBT]), percutaneous biopsies or placement of vascular access device ? 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury
Major surgical procedure, open biopsy or significant traumatic injury =< 28 days prior to registration
Major surgery or significant traumatic injury =< 28 days prior to the first LMB-100 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
Or a traumatic brain injury will be excluded
Patients who have had or are planning to have the following invasive procedures are not eligible:\r\n* Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 14 days prior to initiation of protocol therapy; there should be no anticipation of need for major surgical procedures during the course of the study\r\n* Central line placement or subcutaneous port placement is not considered major surgery; external central lines must be placed at least 3 days prior to initiation of protocol therapy and subcutaneous ports must be placed at least 7 prior to initiation of protocol therapy
Major surgery or significant traumatic injury within 2 weeks of run-in
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days of day 1 of therapy
A minimum time period must elapse between the end of a previous treatment and start of study therapy:\r\n* 1 week from the completion of radiation therapy for brain metastases\r\n* 4 weeks from the completion of chemotherapy or any experimental therapy\r\n* 4 weeks from prior major surgery (such as open biopsy or significant traumatic injury)
Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to on-study date, or anticipation of need for major surgical procedure during the course of the study
Major surgical procedure or significant traumatic injury within 14 days prior to first dose of study drug treatment on Study Day 1 of Period A, or anticipation of the need for major surgery during study treatment
REGORAFENIB EXCLUSION CRITERIA: Major surgical procedure or significant traumatic injury within 28 days before start of regorafenib
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, anticipation of need for major surgical procedure during the course of the study; as an example, port placement or core biopsies are not considered major surgical procedures
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib
No major surgical procedure or significant traumatic injury within 6 weeks prior to study registration, and must have fully recovered from any such procedure; date of surgery (if applicable) or the anticipated need for a major surgical procedure within the next six months; Note: the following are not considered to be major procedures and are permitted up to 7 days before therapy initiation: thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures
Major surgery or significant traumatic injury occurring within 21 days prior to treatment
Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury
Patients who have had a major surgical procedure, open biopsy, or significant traumatic injury with poorly healed wound within 6 weeks prior to first dose of study drug; or anticipation of need for major surgical procedure during the course of the study (other than defined by protocol); or fine needle aspirations or core biopsies within 7 days prior to first dose of study drug
Major surgical procedure, open biopsy, or significant traumatic injury within 14 days prior to day 1 or anticipation of need for major non-cranial surgical procedure during the course of the study
Significant traumatic injury within the past 4 weeks.
Minimum interval since last major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy, or significant traumatic injury is 4 weeks prior to registration; minimum interval since minor procedures, percutaneous biopsies or placement of vascular access device is 1 week prior to registration; patients must have recovered from side effects of such procedure or injury prior to registration
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, anticipation of need for major surgical procedure during the course of the study
Surgery (including open biopsy), significant traumatic injury within 28 days prior to randomization, minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion is allowed
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug
Invasive procedures defined as follows:\r\n* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to day 1 therapy\r\n* Anticipation of need for major surgical procedures during the course of the study\r\n* Core biopsy within 7 days prior to day 1 (D1) therapy
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of FOLFIRI + bevacizumab initiation or anticipation of need for major surgical procedure during the course of the study
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of study drug (56 days for hepatectomy, open thoracotomy, major neurosurgery) or anticipation of need for major surgical procedure during the course of the study
Major surgical procedure or significant traumatic injury within 28 days prior to study drug administration
History of a major surgical procedure or a significant traumatic injury within 14 days prior to commencing treatment, or the anticipation of the need for a major surgical procedure during the course of the study.
Major surgery or significant traumatic injury within 4 weeks of starting study treatment.
Major surgery or significant traumatic injury within 4 weeks of starting study treatment.
Subjects must have recovered from the effects of major surgery requiring general anesthetic or significant traumatic injury at least 14 days before Study Day 0.
Major surgical procedure (including open biopsy, excluding central line intravenous (IV) and port-a-cath placement) within ? 14 days prior to initiating study treatment, or anticipation of the need for major surgery during the course of the study treatment
Major surgical procedure or significant traumatic injury within 28 days before the first dose of study drug or anticipation of the need for major surgery during the course of study treatment.
Surgery (including open biopsy), significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during study treatment
Major surgery or significant traumatic injury that is not recovered at least 14 days before the initiation of thoracic radiation therapy
Had major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of treatment on study
Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to being registered for protocol therapy
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration (biliary stenting or percutaneous biliary drainage are not included)
Major surgical procedure, open biopsy, or significant traumatic injury less than 3 weeks or those who receive minor surgical procedures (eg core biopsy or fine needle aspiration) within 1 week from first dose of first study drug administration
Patients who have had or are planning to have the following invasive procedures are not eligible:  \r\n* Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrollment\r\n* Central line placement or subcutaneous port placement is not considered major surgery but must be placed at least 3 days prior to enrollment for external lines (e.g. Hickman or Broviac) and at least 7 days prior to enrollment for subcutaneous port\r\n* Core biopsy within 7 days prior to enrollment\r\n* Fine needle aspirate within 7 days prior to enrollment\r\n* NOTE: for purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapy
Patients who have had or are planning to have the following invasive procedures are not eligible:\r\n* Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrollment\r\n* Subcutaneous port placement or central line placement is not considered major surgery; external central lines must be placed at least 3 days prior to enrollment and subcutaneous ports must be placed at least 7 days prior to enrollment\r\n* Core biopsy within 7 days prior to enrollment\r\n* Fine needle aspirate within 7 days prior to enrollment\r\n* NOTE: for purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapy
Invasive procedures defined as follows:\r\n* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to day 1 therapy\r\n* Anticipation of need for major surgical procedures during the course of the study\r\n* Core biopsy within 7 days prior to day 1 therapy
Patients who have a major surgical procedure, or significant traumatic injury within 28 days prior to the first date of treatment on this study, or anticipation of need for major surgical procedure during the course of the study; patients with placement of vascular access device or core biopsy within 7 days prior to the first date of treatment on this study
Major surgery or significant traumatic injury within 4 weeks of first study drug
Patients with invasive procedures or anticipation of invasive procedures within the following timeframes as defined below:\r\n* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of bevacizumab therapy (cycle 2)\r\n* Major surgical procedure anticipated during the course of the study\r\n* Core biopsy within 7 days prior to the first date of bevacizumab therapy (cycle 2)
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study
Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to randomization on this study
This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients who have had a major surgical procedure, open biopsy, dental extractions or other dental surgery/procedure that results in an open wound, or significant traumatic injury within 28 days prior to the first date of treatment on this study, or anticipation of need for major surgical procedure during the course of the study; patients with placement of vascular access device or core biopsy within 7 days prior to the first date of treatment on this study
Craniotomy or any other major surgery, open biopsy, or significant traumatic injury within 4 weeks of enrollment
Major surgery, open biopsy or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatment.
Patients who have had a major surgery or significant traumatic injury within 4 weeks from day 1 of study drug
No major surgical procedure or significant traumatic injury within 6 weeks prior to study registration, and must have fully recovered from any such procedure; date of surgery (if applicable). Note: the following are not considered to be major procedures and are permitted up to 7 days before therapy initiation: Thoracentesis, paracentesis, port placement, laparoscopy, thorascopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures
No major surgical procedures, open biopsy or significant traumatic injury =< 28 days prior to registration or anticipation of need for elective or planned major surgical procedure during the study; core biopsy or other minor surgical procedures =< 7 days prior to registration
Major surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment
Patients are excluded if they have had a surgical procedure or a significant traumatic injury within 28 days prior to randomization
Major surgery or significant traumatic injury within 4 weeks prior to study entry.
Major surgery (including ostomy reversal), open biopsy or significant trauma injury, within 28 days prior to randomization.
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, or anticipated need for major surgical procedure during the course of the study, or fine needle aspirations or core biopsies within 7 days prior to day 0
undergone major surgery or suffered from significant traumatic injury
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during course of the study.
The subject had a major surgical procedure, substantial open biopsy, or significant traumatic experience within 28 days before the Day 1 visit, or anticipation of need for major surgical procedure during the course of the study.
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
No major surgical procedure or significant traumatic injury within 6 weeks prior to study registration, and must have fully recovered from any such procedure; date of surgery (if applicable). Note: the following are not considered to be major procedures and are permitted up to 7 days before therapy initiation: Thoracentesis, paracentesis, port placement, laparoscopy, thorascopy, tube thoracostomy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug
Major surgery, or significant traumatic injury occurring within 21 days prior to treatment
Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to study enrollment, or anticipation of need for major surgical procedure during the course of the study; minor surgical procedures including placement of a vascular access device, within 2 days of the first study treatment
have experienced any of the following: a major surgical procedure, significant traumatic injury, non-healing wound, peptic ulcer, or bone fracture less than or equal to 28 days prior to enrollment, or placement of a subcutaneous venous access device less than or equal to 7 days prior to the first dose of study treatment unless the procedure is of low risk of bleeding in the judgment of the investigator
Have had a major surgical procedure or significant traumatic injury including nonhealing wound, peptic ulcer, or bone fracture ?28 days prior to randomization.
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication.
Had major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of treatment on study
Major surgery or significant traumatic injury within 8 weeks of first study drug; a core pancreatic or liver biopsy does not preclude the patient from the study
Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study
Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment date, anticipation of need for major surgical procedure during the course of the study
Fully recovered from the effects of any major surgery or significant traumatic injury prior to the first dose of study treatment
Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study treatment
Subject has undergone a major surgical procedure, open biopsy, radiofrequency ablation or has experienced a significant injury within 28 days prior to enrollment
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study; minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0
Major surgical procedure, open biopsy, or significant traumatic injury =< 28 days prior to registration (=< 56 days for hepatectomy, open thoracotomy, major neurosurgery) or anticipation of need for major surgical procedure during the course of the study
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting nivolumab and bevacizumab
Major surgical procedure, open biopsy, or significant traumatic injury =< 56 days prior to randomization
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Subjects who have not recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment
Major surgical procedure, open biopsy, or significant traumatic injury =< 28 days prior to randomization
Participants may not have a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib
Patients who have a major surgical procedure, or significant traumatic injury within 28 days prior to the first date of treatment on this study, or anticipation of need for major surgical procedure during the course of the study; patients with placement of vascular access device or core biopsy within 7 days prior to the first date of treatment on this study
Major surgery, or significant traumatic injury within 4 weeks prior to study entry
Major surgical procedure, open biopsy, or significant traumatic injury =< 4 weeks prior to registration/randomization; (port-a-cath placement does not count as a major surgical procedure and patients can be enrolled at any time after placement)
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgery, open biopsy or significant traumatic injury within 2 weeks of first dose of study drug
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgery or significant traumatic injury within 4 weeks of starting study treatment.
Major surgery or significant traumatic injury within 4 weeks of first study drug
Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrollment
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drug
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drug
Patients must not have experienced any major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration, or be anticipated to need a major surgical procedure during the course of the study; NOTE: the exception is craniotomy; patients with brain tumors who have undergone craniotomy or intracranial biopsy must be cleared by their neurosurgeon to participate at the time of registration
Invasive procedures defined as follows:\r\n* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to day 1 therapy\r\n* Brain biopsy within 28 days prior to day 1 of therapy (wounds must be fully healed from brain biopsies performed more than 28 days prior to day 1 of therapy)\r\n* Anticipation of need for major surgical procedures during the course of the study\r\n* Core biopsy within 7 days prior to day 1 of therapy
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration (with the exception of craniotomy)
Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug,
For patients who have had a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, or anticipate the need for such while on active treatment, may participate and receive bevacizumab at the start of the second or third cycle as they would under standard care; placement of vascular access device is not considered major surgery, but the incision must have healed before initiation of treatment
Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical procedure, open biopsy, or significant traumatic injury =< 28 days or core biopsy =< 7 days prior to randomization
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 or anticipation of need for major surgical procedure during the course of the study
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day -3 or anticipation of need for major surgical procedure during the course of the study; (a major surgical procedure constitutes an invasive procedure which requires general anesthetic support, hospitalization, and supportive care such as laparotomy, laminectomy, etc.)
Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to being registered for protocol therapy
Patients within 28 days post major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic), open biopsy, or significant traumatic injury to avoid wound healing complications; minor procedures and percutaneous biopsies or placement of vascular access device without complications require 48 hours prior to study entry
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of treatment or anticipation of need for major surgical procedure during the course of the study
Major surgical procedure (including craniotomy) or significant traumatic injury less than 28 days or those who receive minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 7 days
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of day 1 of treatment with FOLFIRI
Major surgical procedure, open biopsy, or significant traumatic injury other than craniotomy within 28 days prior to Day 1, anticipation of need for major surgical procedure during the course of the study
Has had major surgery, open biopsy, or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatment
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment.
Major surgery or traumatic injury within 28 days of randomization
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 therapy
No major surgery, open biopsy or significant traumatic injury within 4 weeks of start of first dose
Major surgical procedure or significant traumatic injury, radiotherapy, chemotherapy, targeted therapy, hormone therapy, or other anticancer therapy.
Major surgical procedure or significant traumatic injury, as defined by the site investigator, within 28 days before study registration.
Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before enrollment
Major surgical procedure, open biopsy (excluding skin cancer resection), or significant traumatic injury within 14 days of initiating study drug (unless the wound has healed) or anticipation of the need for major surgery during the study.
Major surgery, open biopsy or significant traumatic injury within 4 weeks of starting therapy
Major surgery or significant traumatic injury < 28 days prior to the first RO6927005 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
Major surgical procedure or significant traumatic injury within 28 days before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 3 weeks before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 3 weeks before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of therapy
Major surgical procedure, open biopsy, or significant traumatic injury, within 28 days prior to day 1, anticipation of need for major surgical procedure during the course of the study; (minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 1; bone marrow aspiration +/- biopsy is allowed)
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during course of study
Patients may not have had a major surgical procedure, open biopsy (excluding skin cancer resection, cutaneous/subcutaneous melanoma metastasis resection or biopsy or vascular access device insertion), or significant traumatic injury within 28 days prior to Day 1, or have an anticipated need for major surgical procedure or a planned elective surgical procedure during the course of the study.
Patients with contraindications to anticoagulation therapy for deep venous thrombosis such as:\r\n* Patients on full treatment dose of anticoagulation such as those patients being treated for pulmonary embolus\r\n* Presence of central nervous system or brain metastases\r\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1\r\n* Anticipation of need for major surgical procedure during the course of the study\r\n* Those patients that develop DVTs during the study will be treated with anticoagulants and in certain cases, will continue on the protocol
Major surgical procedure, open biopsy, or significant traumatic injury less than 4 weeks or those who receive minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 1 week from first dose of first study drug administration
Major surgical procedure or significant traumatic injury within 28 days prior to day 1 or anticipation of the need for major surgery during the course of study treatment
Major surgery or significant traumatic injury within 14 days of Cycle 1 Day 1.
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the first dose of study treatment or anticipation of need for major surgical procedure during the course of the study
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization, or anticipation of need for major surgical procedure during the course of the study
History of major surgery or traumatic injury =< 28 days prior to registration or other major anticipated procedures requiring general anesthesia during study participation
Major surgical procedure or significant traumatic injury within 4 weeks prior to the first dose of study-drug treatment in Cycle 1, or anticipation of the need for major surgery during the course of study treatment
Significant traumatic injury or major surgery (major surgery means opening of a body cavity, eg, thoracotomy, laparotomy, laparoscopic organ resection, and major orthopedic procedures, eg, joint replacement, open reduction and internal fixation) within 21 days of scheduled dosing day 1;
Significant traumatic injury within 3 weeks prior to initiation of study treatment
Major surgery or significant traumatic injury within 4 weeks of first study treatment from which the subject has not fully recovered
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the first dose of study treatment or anticipation of need for major surgical procedure during the course of the study
Major surgical procedure or significant traumatic injury within 28 days prior to\n             randomization or anticipation of the need for major surgery during the course of\n             study treatment
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, or anticipation of need for major surgical procedure during the course of the study
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1 or abdominal surgery, abdominal interventions or significant abdominal traumatic injury within 60 days prior to Day 1 of Cycle 1
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the first dose of study treatment or anticipation of need for major surgical procedure during the course of the study
Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug, or planned surgery requiring general anesthesia
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury or anticipation of need for major surgical procedure during the course of the study; core biopsy or other minor surgical procedure, eg placement of a vascular access device, are excluded from this requirement
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the first dose of study treatment or anticipation of need for major surgical procedure during the course of the study
Major surgery or significant traumatic injury within 4 weeks of starting study treatment.
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgical procedure or significant traumatic injury within 28 days before enrollment or anticipation of the need for major surgery during the course of study treatment
Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury
History of invasive procedures defined as follows:            \r\n* Major surgical procedure, open biopsy, or significant traumatic injury =< 28 days prior to registration\r\n* Anticipation of need for major surgical procedures during the study\r\n* Core biopsy =< 7 days prior to registration
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before registration
Craniotomy or any other major surgery, open biopsy, or significant traumatic injury within 4 weeks of enrollment
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of treatment (or anticipated need during study)
Major surgical procedures, or significant traumatic injury =< 14 days prior to registration or anticipation of need for elective or planned major surgical procedure during the course of the study
Patient who has undergone the following invasive procedures: Major surgical procedure, open biopsy or significant traumatic injury < 14 days prior to starting study drug or has not recovered from side effects of such therapy, anticipation of need for invasive surgical procedure during the course of the study, biopsy within 7 days prior to starting study drug
Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug, or planned surgery requiring general anesthesia
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug
Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to commencing study treatment, or anticipation of need for a major surgical procedure during the course of the study;
A major surgical procedure or significant traumatic injury within 28 days of beginning treatment, or anticipation of the need for major surgery during the course of the study; in addition, if a patient has not yet recovered from prior minor surgery (such as central venous access device or fine needle aspiration biopsy)
Significant traumatic injury within 4 weeks before Cycle 1, Day 1
Patients with or with anticipation of a non-study related invasive procedure defined as followed: major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of bevacizumab; major non-study related surgical procedure anticipated during the course of the study; core biopsy within 7 days prior to first date of bevacizumab
Any serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to starting treatment with bevacizumab; if surgically cleared for chemotherapy on trial, bevacizumab may be delayed as clinically indicated up to 8 weeks after such procedures
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug
Patients who have not recovered from the side effects of a major surgery or significant traumatic injury or patients that may require major surgery during the course of the study
Major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks and minor procedures (including percutaneous biopsies, placement of vascular access device, laparoscopy +/- biopsy) =< 1 week prior to starting study treatment; patients who have minor procedure(s) > 1 week prior to starting study treatment and have recovered from side effects of such procedure are eligible
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication; minor procedures such as diagnostic laparoscopy, percutaneous biopsy and paracentesis within 14 days before start of study medication
Undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 28 days prior to study registration, or had minor procedures, percutaneous biopsies or placement of vascular access device =< 7 days prior to study registration, or have not recovered from side effects of such procedure or injury
Full recovery from the effects of any major surgery or significant traumatic injury within 14 days prior to the first dose of study treatment
Major surgical procedure or significant traumatic injury within 14 days prior to first dose of study drug or anticipation of the need for major surgery during study treatment
No excess risk of bleeding (any of the following):\r\n* Bleeding diathesis or coagulopathy\r\n* Thrombocytopenia\r\n* Major surgical procedure, open biopsy, or significant traumatic injury within the past 28 days or anticipation of need for major surgical procedure during the course of the study\r\n* Minor surgical procedures, stereotactic biopsy, fine needle aspiration, or core biopsy within the past 7 days
Patients with a history of traumatic brain injury prior to tumor diagnosis are not eligible
Significant traumatic injury or major surgical procedure within 4 weeks prior to starting study treatment
Major surgery such as intra-thoracic, intra-abdominal or intra-pelvic (with the exception of craniotomy), open biopsy or significant traumatic injury ? 4 weeks prior to registration, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device ? 1 week prior to registration, or who have not recovered from side effects of such procedure or injury.
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 or anticipation of need for major surgical procedure during the course of the study
Major surgical procedure or significant traumatic injury within 28 days before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1
Major surgical procedure or significant traumatic injury within 4 weeks prior to initiation of study drug, or anticipation of need for major surgical procedure during the course of the study
Major surgical procedure, traumatic injury, non-healing wound, or peptic ulcer ?28 days prior to randomization.
Major surgery or significant traumatic injury occurring within 4 weeks before randomization
Has had a major surgical procedure, other than for HNC, or significant traumatic injury within 4 weeks prior to the initiation of RT; anticipation of need for major surgical procedure during the course of the study
History of traumatic brain injury
Craniotomy or any other major surgery, open biopsy, or significant traumatic injury within 4 weeks of randomization
Recovery from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment
Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study drug treatment in Cycle 1, or anticipation of the need for major surgery during the course of study treatment
Major surgical procedure or significant traumatic injury within 6 weeks prior to study registration or not fully recovered from any such procedure